Preservation of Diastolic Function by Fenofibrate in Patients with Dyslipidemia

Preservation of Diastolic Function by Fenofibrate in Patients with Dyslipidemia - Cardioprotective Effect of Fenofibrate

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002431

Enrollment

Registered

2009-09-02

Start date

2009-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dyslipidemia

Interventions

Hyper TG patients will be administered with fenofibrate (67-200mg). They will be examined by UCG to assess the cardiac dysfunction.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: high TG patients (over 150mg/dl)

Exclusion criteria

Exclusion criteria: patients with systolic dysfunction (EF below 50%) patients with renal disorders (serum creatinine 2.0mg/dl over) patients with previous or current cancer

Design outcomes

Primary

Measure	Time frame
diastolic function, serum lipid profile	—

Secondary

Measure	Time frame
plasma glucose, HbA1c, urinary 8OHdG, urinary NOx, adiponectin	—

Countries

Japan

Contacts

Public ContactKen-ichi Aihara

The University of Tokushima, Graduate School of Health Biosciences Medicine and Bioregulatory Sciences

aihara@clin.med.tokushima-u.ac.jp088-633-7120

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026